Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Gilead Sciences, Inc (NASDAQ: GILD) closed the day trading at $97.88 down -4.80% from the previous closing price of $102.81. In other words, the price has decreased by -$4.80 from its previous closing price. On the day, 11.4 million shares were traded.
Ratios:
For a better understanding of GILD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.84. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.30. In the meantime, Its Debt-to-Equity ratio is 1.43 whereas as Long-Term Debt/Eq ratio is at 1.33.
On March 04, 2025, Oppenheimer reiterated its Outperform rating and also lowered its target price recommendation from $115 to $132.
Deutsche Bank Upgraded its Hold to Buy on February 18, 2025, while the target price for the stock was maintained at $120.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 15 ’25 when Dickinson Andrew D sold 2,500 shares for $106.40 per share. The transaction valued at 266,000 led to the insider holds 168,174 shares of the business.
ANDREW DICKINSON bought 2,500 shares of GILD for $266,000 on Apr 15 ’25. On Mar 17 ’25, another insider, Dickinson Andrew D, who serves as the Chief Financial Officer of the company, sold 2,500 shares for $110.53 each. As a result, the insider received 276,325 and left with 170,674 shares of the company.
Valuation Measures:
As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.60, and their Forward P/E ratio for the next fiscal year is 11.48. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.25 while its Price-to-Book (P/B) ratio in mrq is 6.39.
Stock Price History:
Over the past 52 weeks, GILD has reached a high of $119.96, while it has fallen to a 52-week low of $62.07. The 50-Day Moving Average of the stock is -9.93%, while the 200-Day Moving Average is calculated to be 5.43%.
Shares Statistics:
A total of 1.25B shares are outstanding, with a floating share count of 1.24B. Insiders hold about 0.19% of the company’s shares, while institutions hold 86.59% stake in the company.
Earnings Estimates
The current rating of Gilead Sciences, Inc (GILD) reflects the combined expertise of 19.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $2.17, with high estimates of $2.4 and low estimates of $1.99.
Analysts are recommending an EPS of between $8.6 and $7.71 for the fiscal current year, implying an average EPS of $7.98. EPS for the following year is $8.47, with 27.0 analysts recommending between $10.05 and $6.45.
Revenue Estimates
19 analysts predict $6.95B in revenue for the current quarter. It ranges from a high estimate of $7.27B to a low estimate of $6.74B. As of the current estimate, Gilead Sciences, Inc’s year-ago sales were $6.95BFor the next quarter, 19 analysts are estimating revenue of $7.39B. There is a high estimate of $7.58B for the next quarter, whereas the lowest estimate is $7.2B.
A total of 27 analysts have provided revenue estimates for GILD’s current fiscal year. The highest revenue estimate was $29.45B, while the lowest revenue estimate was $28.28B, resulting in an average revenue estimate of $28.65B. In the same quarter a year ago, actual revenue was $28.75BBased on 28 analysts’ estimates, the company’s revenue will be $29.71B in the next fiscal year. The high estimate is $31.88B and the low estimate is $28.7B.
